HER2 testing is routinely recommended for all newly diagnosed breast cancers, and a re-characterization can be performed in some cases after neoadjuvant treatment and/or in case of tumor progression if a tissue sample is available (Viale and Fusco 2021; Wolff et al., 2018). Here, ERBB2 is linked to breast cancer.